METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for tough prostate cancer
Disease control CompletedThis study tested a new drug (CPI-1205) combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in 175 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find the safest dose and see if the combination helps shr…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
Finnish prostate cancer study reveals Real-World treatment patterns
Knowledge-focused CompletedThis study collected information from over 1,000 men in Finland with metastatic prostate cancer that has spread. Researchers looked at patient details, what treatments they received, and how well those treatments worked. The goal was to better understand the disease and its impac…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC